0001209191-19-023661.txt : 20190404 0001209191-19-023661.hdr.sgml : 20190404 20190404164353 ACCESSION NUMBER: 0001209191-19-023661 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180515 FILED AS OF DATE: 20190404 DATE AS OF CHANGE: 20190404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Irving Bryan CENTRAL INDEX KEY: 0001715542 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 19732673 MAIL ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2018-05-15 2018-05-14 0 0001175505 FIVE PRIME THERAPEUTICS INC FPRX 0001715542 Irving Bryan 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, Chief Scientific Officer Common Stock 2018-05-15 4 A 0 3750 0.00 A 24750 D Employee Stock Option (right to buy) 17.75 2018-05-15 4 A 0 22500 0.00 A 2028-05-14 Common Stock 22500 22500 D This amendment is being filed to reflect the correct transaction date of May 15, 2018 with respect to the restricted stock and stock option awards initially disclosed in the reporting person's Form 4 filed with the Securities and Exchange Commission on May 14, 2018 (the "Original Form 4"). The Original Form 4 inadvertently reported a transaction date of May 10, 2018 for such awards. Additionally, the exercise price and expiration date of the stock option award disclosed in Table II of the Original Form 4 are amended accordingly based on the correct transaction date of May 15, 2018. Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of May 15, 2019, 2020 and 2021, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date. The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following May 15, 2018, provided the reporting person provides services to the Company through each such date. /s/ Francis Sarena, Attorney-in-fact 2019-04-04